What’s new in the diagnosis of pancreatic cancer: a patent review (2011-present)

References

• Siegel R, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. ​​​​​
   PubMed Web of Science ®Google Scholar
• Poruk KE, Firpo MA, Adler DG, et al. Screening for pancreatic cancer: why, how, and who? Ann Surg. 2013;257(1):17–26.
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117.
   PubMed Web of Science ®Google Scholar
• Overbeek KA, Cahen DL, Canto MI, et al. Surveillance for neoplasia in the pancreas. Best Pract Res Clin Gastroenterol. 2016;30(6):971–986.
   PubMed Web of Science ®Google Scholar
• Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804.
   PubMed Web of Science ®Google Scholar
• Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56:S82–S86.
   PubMed Web of Science ®Google Scholar
• Langner C. [Hereditary gastric and pancreatic cancer]. Pathologe. 2017;38(3):164–169.
   PubMed Web of Science ®Google Scholar
• Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett. 2016;381:269–277.
   PubMed Web of Science ®Google Scholar
• Urayama S. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters. World J Gastroenterol. 2015;21:1707–1717.
   PubMed Web of Science ®Google Scholar
• Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73(3):485–492.
   PubMed Web of Science ®Google Scholar
• Zhang X-P, Yu Z-X, Zhao Y-P, et al. Current perspectives on pancreatic serous cystic neoplasms: diagnosis, management and beyond. World J Gastrointest Surg. 2016;8(3):202–211.
   PubMed Web of Science ®Google Scholar
• De la Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626–632.
   PubMed Web of Science ®Google Scholar
• Dickson D. A prospective longitudinal study of CA 19-9 as an aid in monitoring disease in patients with pancreatic cancer. ClinicalTrials.gov Identifier: NCT02250638. 2015.
   Google Scholar
• Zhang G, Pronyuk K, Kuliesh O, et al. Pancreatic protein biomarker, uses of same, detection chip therefor, and detection device. WO2017008388A1. 2017.
   Google Scholar
• Zhang G, Pronyuk K, Kuliesh O, et al. Detection reagent kit and detection system for pancreatic cancer protein biomarkers. WO2017008389A1. 2017.
   Google Scholar
• Kamlage B, Reszka R, Schatz P, et al. Means and methods for diagnosing Pc in a subject based on biomarker panel. WO2016207391A1. 2016.
   Google Scholar
• Nitto Boseki Co., Ltd. Marker for detecting pancreatic cancer. US 20150104816A1. 2015.
   Google Scholar
• Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016;2016:1–10.
   Web of Science ®Google Scholar
• Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175–2181.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jin Z, Li Z, et al. Computer-aided method for distinguishing ultrasound endoscope ​​​​​image of pancreatic cancer. CN102122356A. 2011.
   Google Scholar
• Kamata K, Kitano M, Omoto S, et al. New endoscopic ultrasonography techniques for pancreaticobiliary diseases. Ultrasonography. 2016;35(3):169–179.
   PubMed Web of Science ®Google Scholar
• Saftoiu A, Vilmann P, Bhutani MS. The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Endosc Ultrasound. 2016;5(6):368–372.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Nat Cancer Center. Plasma biomarker panel for diagnosing pancreatic cancer. WO2016195051A1. 2016.
   Google Scholar
• Exosome Co Ltd. Cancer diagnostic or prognostic biomarker composition comprising Del-1 protein positive exosome. WO2016148313A1. 2016.
   Google Scholar
• Queen Mary University of London. Biomarkers for pancreatic cancer. WO2016124947A1. 2016.
   Google Scholar
• Hutchinson Fred Cancer Res. Pancreatic cancer diagnostic. WO2016049045A1. 2016.
   Google Scholar
• Roland A, Daniel A. Method for determining a subject’s probability to suffer from pancreatic cancer. WO2016030426A1. 2016.
   Google Scholar
• University of Lubeck, Randox Laboratories Ltd. Combinaisons de biomarqueurs pour utilisation dans le depistage du cancer du pancreas. WO2016001249A1. 2016.
   Google Scholar
• Oliver F; BATHE. Uti Limited Partnership. Metabolomics for diagnosing pancreatic cancer. WO2016097860A1. 2016.
   Google Scholar
• Cordelier P; INSERM. Methods for the diagnosis of pancreatic cancer. WO2016113233A1. 2016.
   Google Scholar
• Lg Electronics Inc, UnivYonseiIacf. Method for extracting biomarker for diagnosing pancreatic cancer, computing device therefor, biomarker for diagnosing pancreatic cancer and device for diagnosing pancreatic cancer including the same. US2016055297A1. 2016.
   Google Scholar
• Zhualin R. Method of taking IL-11 (interleukin) as biomarker in diagnosis and prognostic evaluation of pancreatic cancer. CN104698170A. 2015.
   Google Scholar
• Yongseo University. Composition for pancreatic cancer diagnosis comprising complement factor I-specific binding polypeptide or antibody. KR20150030046A. 2011.
   Google Scholar
• Ballard KL, Mcdade RL, Spain MD, et al. Methods of diagnosing pancreatic cancer and methods related thereto. WO2015157557A1. 2015.
   Google Scholar
• Pouria J, Hoheisel J, Riazalhosseini Y. Pancreatic cancer therapy and diagnosis. WO2015158890A2. 2015.
   Google Scholar
• Liu D, Gold DV, Chang CH, et al.; Immunomedics, Inc. Anti-mucin antibodies for early detection and treament of pancreatic cancer. CA2899811A1. 2014.
   Google Scholar
• Gold DV, Goldenberg DM; Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer. US20140112864A1. 2014.
   Google Scholar
• Univ Tohoku. Pancreatic cancer biomarker. JP2013027387A. 2013.
   Google Scholar
• Fazlul S. Michigan center for pancreatic cancer molecular diagnosis: the serum protein microarray project. ClinicalTrials.gov Identifier: NCT00897494. 2016.
   Google Scholar
• Hogendorf P, Durczyński A, Skulimowski A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: preliminary report. Cancer Biomark. 2016;16(4):537–543.
   PubMed Web of Science ®Google Scholar
• Kensuke T, Meizi J, Wataru T, et al. Levels of soluble LR11/SorLA are highly increased in the bile of patients with biliary tract and pancreatic cancers. Clin Chim Acta. 2016;457:130–136.
   PubMed Web of Science ®Google Scholar
• Kaur S, Baine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6(5):597–612.
   PubMed Web of Science ®Google Scholar
• Liu D, Gold DV, Chang CH, et al.; Immunomedics Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer. US2016090413A1. 2016.
   Google Scholar
• Novelli F, Tomaino B, Cappello P. An isolated monophosphorylated peptide derived from human alpha-enolase useful for diagnosis and treatment of pancreatic adenocarcinoma, antibodies directed against the said monophosphorylated peptide, and uses thereof. WO 2011030302 A1. 2011.
   Google Scholar
• Novelli F, Cappello P, Capello M. A method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma. WO 2013186748 A1. 2013.
   Google Scholar
• Jaffee EA, Jhaveri DT, Anders R; Univ Johns Hopkins. Diagnostic biomarkers and therapeutic targets for pancreatic cancer. US2016327560A1. 2016.
   Google Scholar
• Khosavifar R, Libermann TA, Bhasin MK; Beth Israel Deaconess Medical Center Inc. Methods and kits for the diagnosis and treatment of pancreatic cancer. US2016348182A1. 2016.
   Google Scholar
• Moffitt R, Yeh JJ, Rashid NU; Univ North Carolina. Methods and compositions for prognostic and/or diagnostic subtyping of pancreatic cancer. WO2016061252A1. 2016.
   Google Scholar
• Vogelstein B, Kinzler KW, Parsons DW, et al.; The Johns Hopkins University. Diagnostic method using palb2. US20160032406A1. 2012.
   Google Scholar
• Zhou B, Xu JW, Cheng YG, et al. Early detection of pancreatic cancer: where are we now and where are we going? Int J Cancer. 2017;15;141(2):231–241.
   Web of Science ®Google Scholar
• Schmittgen TD, Brackett DJ; Univ Oklahoma, Ohio State Innovation Foundation. MicroRNA expression profile associated with pancreatic cancer. US2014357702A1. 2014.
   Google Scholar
• Li L, Ring G; Inst Basic Med Sciences Pla. Use of micro-RNA molecule miR491-5p in treatment and/or diagnosis and/or prognosis of pancreatic cancer. CN103861121A. 2014.
   Google Scholar
• Johansen JS, Schultz NA, Wojdemann M; Herlev Hospital. Microrna biomarkers for prognosis of patients with pancreatic cancer. US20140106985A1. 2014.
   Google Scholar
• Uday Navaneethan MD. Lipidomics, proteomics, micro RNAs and volatile organic compounds biomarkers in bile and serum in the diagnosis of malignant biliary strictures. ClinicalTrials.gov Identifier: NCT02531607. 2016.
   Google Scholar
• Searson PC, Lee KH, Konstantopoulos K, et al.; The Johns Hopkins University. Device for capture, enumeration, and profiling of circulating tumor cells. US2012100560A1. 2012.
   Google Scholar
• Univ Jinan. Preparation method and application of PC immunosensor based on gold electrodeposition and Au@Ag/CuO-GS as markers. CN104459132A. 2015.
   Google Scholar
• Yueyun L, Liping J, Jian H, et al.; Univ Shandong Technology. Preparation method and application of platinum hybrid copper oxide multi-walled carbon nanotube sensor. CN104181299A. 2014.
   Google Scholar
• Univ Jinan. Preparation method and application of Pt-carbon nitride/graphene carbon nitride tumor marker CA19-9 biological sensor. CN104880559A. 2015.
   Google Scholar
• Han S; Sk Telecom Co Ltd, Seoul Nat UnivR&Db Found. Composition for diagnosing pc and method for diagnosing pancreatic cancer using same. US2016252512A1. 2016.
   Google Scholar
• Si Young Song MD; LG Electronics Inc. Validation of useful markers generated by next generation bio-data based genome research and cohort study (miRNA_Chip). ClinicalTrials.gov Identifier: NCT02807896. 2016.
   Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract. 2008;5:588–599.
   Google Scholar
• Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst. 2010;102:1462–1467.
   PubMedGoogle Scholar
• Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem. 2013;59:147–157.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100:1432–1438.
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18.
   PubMed Web of Science ®Google Scholar
• Morata-Tarifa C, Picon-Ruiz M, Griñan-Lison C, et al. Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity. Sci Rep. 2017;7:39782.
   PubMed Web of Science ®Google Scholar
• Di Gangi IM, Mazza T, Fontana A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7:5815–5829.
   PubMed Web of Science ®Google Scholar
• Sakai A, Suzuki M, Kobayashi T, et al. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Biomark Med. 2016;10:577–586.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu Y, Yuan Z. Circulating tumor cells and circulating tumor DNA provide new insights into pancreatic cancer. Int J Med Sci. 2016;13(12):902–913.
   PubMed Web of Science ®Google Scholar
• Buscail E; University Hospital, Bordeaux. Diagnostic accuracy of circulating tumor cells (CTCs) and onco-exosome quantification in the diagnosis of pancreatic cancer – PANC-CTC. ClinicalTrials.gov Identifier: NCT03032913. 2017.
   Google Scholar
• Kelsen J; Aarhus University Hospital. Circulating tumor cells and tumor DNA in HCC and NET. ClinicalTrials.gov Identifier: NCT02973204. 2016.
   Google Scholar